The 5 Most Interesting Analyst Questions From Medpace's Q4 Earnings Call

Medpace’s fourth quarter was marked by robust top-line growth and a significant year-over-year increase in revenue, but the market responded negatively, likely due to rising cancellations and margin pressure. CEO August Troendle acknowledged that “cancellations were elevated again in Q4,” with the highest backlog cancellations in over a year, particularly impacting the metabolic therapeutic area. This uptick in cancellations and a shift in business mix put downward pressure on operating margin, which declined compared to the prior year. Management described the business environment as “adequate and headed in the right direction,” but did not anticipate the spike in cancellations.

Is now the time to buy MEDP? Find out in our full research report (it’s free for active Edge members).

While we enjoy listening to the management's commentary, our favorite part of earnings calls are the analyst questions. Those are unscripted and can often highlight topics that management teams would rather avoid or topics where the answer is complicated. Here is what has caught our attention.

Our Top 5 Analyst Questions From Medpace’s Q4 Earnings Call

• Christine Raines (William Blair) asked about direct fee revenue growth expectations and headcount needs. CFO Kevin Brady clarified that reimbursable costs are expected to rise slightly, while President Jesse Geiger said hiring will accelerate but remain in the mid- to high-single-digit range.
• Justin Bowers (Deutsche Bank) inquired about the business environment and drivers behind higher cancellations. CEO August Troendle attributed cancellations mainly to metabolic trials and described the environment as “reasonably good” with RFP activity up.
• Ann Hynes (Mizuho Securities) pressed for details on the nature and distribution of cancellations. Troendle explained that cancellations were widespread, not concentrated with any single client or project, and were at the highest level seen in the past year.
• David Windley (Jefferies) sought clarity on concentration risk in metabolic trials and the link to pass-through costs. Troendle noted that metabolic concentration should decrease in 2026, reducing its impact, and pass-throughs have been largely driven by these projects.
• Sean Dodge (BMO Capital Markets) questioned the expected margin dynamics and AI’s role in productivity. Brady cited hiring discipline and retention as the main drivers of margin, while Troendle downplayed near-term AI impact, stating benefits would take years to materialize.

Catalysts in Upcoming Quarters

Looking ahead, our analysts will focus on (1) whether cancellation levels return to historical norms and backlog conversion remains steady, (2) the pace at which metabolic trial mix shifts and its impact on margins, and (3) continued progress in AI and process efficiency initiatives. We will also monitor hiring trends and productivity gains as key contributors to margin stability.

Medpace currently trades at $428.50, down from $530.35 just before the earnings. In the wake of this quarter, is it a buy or sell? See for yourself in our full research report (it’s free).

The Best Stocks for High-Quality Investors

Your portfolio can’t afford to be based on yesterday’s story. The risk in a handful of heavily crowded stocks is rising daily.

The names generating the next wave of massive growth are right here in our Top 5 Strong Momentum Stocks for this week. This is a curated list of our High Quality stocks that have generated a market-beating return of 244% over the last five years (as of June 30, 2025).

Stocks that have made our list include now familiar names such as Nvidia (+1,326% between June 2020 and June 2025) as well as under-the-radar businesses like the once-micro-cap company Kadant (+351% five-year return). Find your next big winner with StockStory today.